Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference.
Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific.
The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC.
In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW.
Blood cancers (ALL, NHL, DLBCL, lymphomas), solid tumors, viral infections, liver and gastrointestinal tract cancers are the top indications in China-based cell & gene therapy trials between 2016 and 2021.
Watch our recent Endpoints News webinar for more information:
EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-T
The award was presented to Novotech during the 6th Cell & Gene Therapy World Asia 2022 conference (14th – 15th September) at the Sheraton Towers, Singapore.
Novotech CEO Dr. John Moller said we are extremely pleased our team has been recognized with this prestigious award at the 6th Cell & Gene Therapy World Asia 2022 conference.
“Cell & gene therapy is driving recent innovations in biotech and it is an honour to be recognized as the CRO at the forefront in Asia-Pacific supporting this vital clinical research.
Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital.
Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success.”
Novotech has recently also been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
Download our latest data reports here:
EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit: https://novotech-cro.com/talk-to-an-expert